Prospective randomized Phase II trial with gemcitabine plus sunitinib versus gemcitabine alone in first-line therapy of metastatic or locally advanced pancreatic cancer, CESAR C-II-004
Laufzeit: 01.01.2010 - 31.12.2013
Kurzfassung
Primary Objective
The primary objective of this study is to evaluate whether the addition of sunitinib to gemcitabine arm A) prolongs the progression-free survival (PFS) compared to gemcitabine alone (arm B) in patients with advanced pancreatic cancer.
Secondary Objectives
Secondary objectives are the characterization of safety and additional efficacy outcomes in the experimental arm A and their exploratory comparison with the arm B.
